The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

Venous thromboembolism, comprising both deep vein thrombosis and pulmonary embolism,
is a chronic illness that affects nearly 10 million people every year worldwide. Strong …

Importance Direct oral anticoagulants (DOACs), comprising apixaban, rivaroxaban,
edoxaban, and dabigatran, are commonly used medications to treat patients with atrial …

within the leg or pelvic veins, and approximately half of all deep-vein thrombi embolize to the
lungs. 1 The annual incidence of pulmonary embolism worldwide is approximately 1 in 1000 …

Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion
(thrombosis and/or pregnancy morbidity), combined with persistently circulating …

Antiplatelet medications remain a cornerstone of therapy for atherosclerotic cardiovascular
and cerebrovascular diseases. In primary prevention (patients with cardiovascular risk …

Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K
antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to …

Background Patients with single‐ventricle physiology who undergo the Fontan procedure
are at risk for thrombotic events associated with significant morbidity and mortality. The …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …